A large 2025 study of more than 7,000 patients showed that serology alone can miss up to 45% of high viral load EBV cases, especially in immunocompromised and adolescent groups. The authors emphasised that using multiple markers such as VCA, EBNA, and EA-D provides greater reliability for distinguishing acute, past, and reactivated infections.
Read more here: https://lnkd.in/evV3ns2J
At AbBaltis, we’re proud to be an award-winning supplier helping IVD developers strengthen their assays. Our EBV Panel includes well-characterised human plasma and serum samples positive for EBV VCA, EBV EBNA, and EBV EA-D, each with IgG, IgM, and IgA profiles validated using leading IVD platforms. These materials support diagnostic assay development, validation, and serological research with confidence.
📦 Free samples available : info@abbaltis.com
to request yours.
🔗 Explore our featured products: https://lnkd.in/ec-7jAk2